Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Replimune Group, Inc. - Common Stock (NQ:REPL)

3.335 +0.530 (+18.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 Next >
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors
From Kirby McInerney LLP
Via GlobeNewswire
Which stocks are experiencing notable movement on Wednesday?
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
From Shriram Properties, Havells To Vesuvius: SEBI RA Sees 15% To 30% Upside In These Six Stocks
Via Stocktwits
This Centene Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi, LLP
Via Business Wire
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm
From Bleichmar Fonti & Auld LLP
Via Business Wire
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Falls Over 100 Points; Coca-Cola Posts Upbeat Earnings
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL
From The Rosen Law Firm, P.A.
Via Business Wire
Gapping stocks in Tuesday's session
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
US Stocks Mixed; General Motors Shares Fall After Q2 Results
Via Benzinga
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval. 
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Replimune Group Inc
Via GlobeNewswire
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
From Replimune Group Inc
Via GlobeNewswire
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
From Replimune Group Inc
Via GlobeNewswire
Earnings Scheduled For May 22, 2025
Via Benzinga
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
From Replimune Group Inc
Via GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune Group Inc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.